Can Bioethics Panels Fix the Problems With the Availability of “Compassionate Use” Experimental Drugs?

<p class="MsoNoSpacing" style="font-size: 11.1999998092651px; line-height: 19.0400009155273px;"><span style="line-height: 22.3999996185303px; font-size: 11.1999998092651px;">On May 7, 2015, <a href="http://www.med.nyu.edu/pophealth/faculty/caplaa01">The New York Times reported</a> that <a href="http://www.jnj.com">Johnson &amp; Johnson</a> (New Brunswick, New Jersey) </span><span style="line-height: 22.3999996185303px; font-size: 11.1999998092651px;">had asked Arthur Caplan, PhD, Professor of Bioethics at New York University School of Medicine </span><span style="line-height: 22.3999996185303px; font-size: 11.1999998092651px;">to create a new panel “that will <a href="http://www.nytimes.com/2015/05/07/business/company-creates-bioethics-panel-on-trial-drugs.html">make decisions about patients’ requests</a> for potentially lifesaving medicine, responding to an emotional debate over whether companies should allow desperately ill people to have access to the drugs before they are approved [by the FDA].” </span></p> <p class="MsoNormal" style="font-size: 11.1999998092651px; line-height: 22.3999996185303px;"><span style="font-size: 11.1999998092651px; line-height: 22.3999996185303px;">“</span><a style="font-size: 11.1999998092651px; ...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care Research Ethics drug safety Research and Development risk syndicated Source Type: blogs